News

MSD has presented a post-hoc analysis of data pooled from studies of 104 weeks in duration, which showed ‘Januvia’ (sitagliptin), when taken alone or in combination with metformin,

Dynavax Technologies has announced the initiation of a phase 3 registration trial for Heplisav hepatitis B vaccine in individuals with chronic kidney disease. A second registration trial, a

Mankind has presented Afresa study data at the 45th Annual Meeting of the European Association for the Study of Diabetes. The data shows that Afresa Inhalation Powder is

Scarab Genomics has introduced ScarabXpress, the latest strain in the multiple-deletion series (MDS) of its Clean Genome E coli. Based on the MDS42 strain, ScarabXpress T7lac contains a

Boston Scientific has announced the settlement of more than a dozen lawsuits involving Johnson & Johnson, including the Palmaz-NIR suit. The company said that all the disputes involved

SeraCare Life Sciences has announced that the company has been awarded two new contracts from the Centers for Disease Control (CDC) and the National Institutes of Health (NIH)

Repros Therapeutics has received further clarification from the Food and Drug Administration (FDA) on the Full Clinical Hold status of Proellex. As announced in early August 2009, and

PolyMedix has initiated dosing and commenced a second clinical trial, a phase 1B pilot proof of concept study, in the US with its anticoagulant reversing agent PMX-60056 under

Keryx Biopharmaceuticals has announced updated clinical results from a phase 2 study of KRX-0401 (perifosine), the company’s PI3K/Akt pathway inhibitor for cancer, as a single-agent treatment for advanced